Long-Acting Injectable Cabotegravir Use and Persistence Over 2 Years
JAMA Network Open · 26.06.2026 · 9 (6) · e2620699
DOI: 10.1001/jamanetworkopen.2026.20699 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 26.06.2026. Verfasst von Shi Hao Ernest Koh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, Pyridones, HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Importance Long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) has superior efficacy vs oral PrEP, and higher LAI–cabotegravir (CAB) persistence may optimize its HIV prevention impact.
Objective
To characterize individuals using LAI-CAB compared with oral PrEP, to describe changes in national LAI-CAB vs oral PrEP use over time, and to examine longitudinal persistence among LAI-CAB users. Design, Setting, and Participants This retrospective cohort study used pharmacy and medical claims from a database that covered a majority of all claims in the US from 2022 to 2024. Participants included persons with 1 or more claim for any PrEP drugs (oral or injectable). Exposure PrEP use during the study period. Main Outcomes and Measures Study outcomes were LAI-CAB use and persistence in care. LAI-CAB use was defined as at least 1 claim, and LAI-CAB yearly persistence was defined as at least 2 LAI-CAB claims for each of 2 biannual periods. Yearly persistence in any type of PrEP (PrEP persistence) was defined as at least 2 claims for PrEP medications (oral or injectable) for each of 2 biannual periods among LAI-CAB users. Multivariable logistic regression models were used to assess variables associated with LAI-CAB use compared with oral PrEP.
Results
From 2022 to 2024, there were 24 194 LAI-CAB users, representing 3% of all 781 040 PrEP users. LAI-CAB users were young (mean [SD] age, 37.1 [11.4] years) and predominantly male (20 642 users [85%]); 656 (3%) were Asian, 4531 (19%) were Black, 4380 (19%) were Hispanic, 13 696 (58%) were White, and 414 (2%) were of other races and ethnicities. Most had commercial insurance (16 334 users [68%]) and had no copayment (13 507 users [82%]). LAI-CAB users were more likely than oral PrEP users to be covered by Medicaid (6256 of 24 194 users [26%] vs 108 589 of 770 833 users [14%]). In the most recent evaluated period (July to December 2024), LAI-CAB accounted for 4% (16 557 of 390 816 users) of PrEP users. Among users with sufficient data, LAI-CAB persistence was 50% (6020 of 12 118 users) at 1 year and 23% (785 of 3381 users) at 2 years. Overall PrEP persistence among LAI-CAB users, including transitions to oral PrEP, was 57% (6879 of 12 118 users) at 1 year and 30% (1019 of 3381 users) at 2 years. A greater proportion of female users initiated LAI-CAB (3551 users [15%]) than oral PrEP (83 274 users [11%]), but 2-year LAI-CAB persistence was lower among female users (61 users [13%]) than among male users (724 users [25%]). Conclusions and Relevance In this national prescription claims cohort study, LAI-CAB use was a small share of overall PrEP use from 2022 to 2024. Approximately one-half of users were persistent in LAI-CAB or in PrEP at year 1, declining to about one-quarter and one-third, respectively, by year 2. The implementation of more effective new PrEP modalities alone is unlikely to substantially alter PrEP use in the US. Instead, structural supports and behavioral interventions are needed to facilitate scale-up of new, highly efficacious modalities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
- OHSU-PSU School of Public Health, Oregon Health & Science University, Portland.
- Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis.
- Department of Health Policy and Management, Emory University, Atlanta, Georgia.
- National Alliance of State and Territorial AIDS Directors, Washington, DC.
Förderung
- NIAID NIH HHS
Zitieren
APA
Koh, S. H. E., Huang, W., Hall, E. W., Jones, J., Zang, X., Yarbrough, C. R., Corbin-Gutierrez, E. E., Sullivan, P. S., & Siegler, A. J. (2026). Long-Acting Injectable Cabotegravir Use and Persistence Over 2 Years. JAMA Network Open, 9(6), e2620699. https://doi.org/10.1001/jamanetworkopen.2026.20699
Vancouver
Koh SHE, Huang W, Hall EW, Jones J, Zang X, Yarbrough CR, et al. Long-Acting Injectable Cabotegravir Use and Persistence Over 2 Years. JAMA Network Open. 2026;9(6):e2620699. doi:10.1001/jamanetworkopen.2026.20699
BibTeX
@article{Koh2026,
author = {Koh, Shi Hao Ernest and Huang, Wenting and Hall, Eric W and Jones, Jeb and Zang, Xiao and Yarbrough, Courtney R and Corbin-Gutierrez, Edwin E and Sullivan, Patrick S and Siegler, Aaron J},
title = {Long-Acting Injectable Cabotegravir Use and Persistence Over 2 Years},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {6},
pages = {e2620699},
doi = {10.1001/jamanetworkopen.2026.20699}
}
EUVIMED